Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

A person's "bioenergetic age"-or how youthfully their cells generate energy-might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research from Weill Cornell ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...